Research

  • Hope for children with Spinal Muscular Atrophy

    Children newly diagnosed with the devastating genetic condition Spinal Muscular Atrophy (SMA) now have access to novel new gene therapy, Zolgensma®, free of charge, thanks to its listing on the Pharmaceutical Benefits Scheme.

    Wednesday 30 March 2022

  • From 10 seizures a day to one a week

    How Bronte went from 10 seizures a day to one a week. A new drug trial brings hope for children with Dravet Syndrome, a severe form of epilepsy.
    Friday 25 March 2022

  • Fewer side effects for kids from COVID vax

    A third of Australian children aged 5-11 years old are experiencing fewer side effects than the rest of the eligible population following their second dose of Pfizer vaccination, according to new surveillance data.
    Friday 18 March 2022

  • Bridging the gap between diagnosis and treatment of genetic conditions

    The genomic revolution is changing the face of modern medicine. In this new era, SCHN is focused on bridging the gap between the ability to diagnose and the ability to offer treatment of genetic conditions – and the results are life changing.
    Monday 22 November 2021

  • eGate wins Internet of Things Health Award

    The Australian-first COVID-19 e-Gate, developed by the University of Sydney and SCHN, has been recognised at the Internet of Things (IoT) Alliance Australia’s 2021 IoT Award, winning the award for the Health category.
    Wednesday 10 November 2021

Pages